88 -2 (40) 2022 — Juraev Muzaffar Gulomovich — D-DIMER LEVEL IN COVID-19 INFECTION ASSOCIATED WITH SECONDARY PNEUMONIA

D-DIMER LEVEL IN COVID-19 INFECTION ASSOCIATED WITH SECONDARY PNEUMONIA

Juraev Muzaffar Gulomovich Andijan State Medical Institute Uzbekistan

Rezume

Since December 2019, a new representative of the human coronavirus, which was recently identified in Wuhan, China, has been officially named by the International Committee on Virus Taxonomy as severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) [1,2,3]. SARS-CoV-2, which belongs to the beta-coronavirus 2b lineage on the phylogenetic tree, is a new strain of RNA viruses that has not been previously identified in humans. Recently, the disease caused by SARS-CoV-2 was named COVID-19 (coronavirus disease 2019) by the World Health Organization (WHO). The number of infected patients worldwide is growing rapidly and has exceeded 100,000 people. In particular, COVID-19 is usually characterized by symptoms from the lower respiratory tract with fever, dry cough and shortness of breath, a manifestation similar to two other diseases caused by coronaviruses, severe acute respiratory syndrome and Middle East respiratory syndrome [5,6,17]. In some patients, severe pulmonary and extrapulmonary complications can lead to respiratory failure and life-threatening events. It was reported that about 50% of patients had elevated D-dimer levels, and abnormal D-dimer levels are associated with a poor prognosis [7,8,9]. Thus, in some stable patients with sudden death, acute organ embolism and infarction should be taken into account. The incidence of deep vein thrombosis and pulmonary embolism was 12.5% and 8.4%, respectively, in cases of COVID-19 [10]. However, careful consideration of traditional anticoagulants may be required, since patients with COVID-19 have an increased risk of bleeding [11,12,13]. Therefore, in our experience, biomarkers that can identify blood clot formation at earlier stages can be used to assess blood clot formation and response to treatment. D-dimers are fibrin breakdown products that have been shown to be useful in the rule of clinical decision-making to exclude pulmonary embolism [14,15,16]. However, the relationship between D-dimmer and COVID-19 and changes in the level during the development of the disease has not been fully reported. In this study, we compared D-dimer levels in COVID-19 patients with bacterial pneumonia, evaluated the use of consecutive D-dimer levels after hospitalization, and studied its relationship with inflammatory markers.

Keywords: D-dimer, COVID-19, bacterial pneumonia, retrospective analysis, highly sensitive C-reactive protein, community-acquired pneumonia.

First page

450

Last page

455

For citation: Juraev Muzaffar Gulomovich D-DIMER LEVEL IN COVID-19 INFECTION ASSOCIATED WITH SECONDARY PNEUMONIA //New Day in Medicine 2(40)2022 450-455 https://clck.ru/eSGug

LIST OF REFERENCES:

1. Чен Н., Чжоу М., Дун Х и др. Эпидемиологические и клинические характеристики 99 случаев новой коронавирусной пневмонии 2019 г. в Ухане, Китай: описательное исследование. Ланцет. 2020; 395 (10223): 507–513. DOI: 10.1016 / S0140-6736 (20) 30211-7.
2. Хуанг Ц., Ван И, Ли Х и др. Клинические особенности пациентов, инфицированных новым коронавирусом 2019 г., в Ухане, Китай. Ланцет. 2020; 395 (10223): 497–506. DOI: 10.1016 / S0140-6736 (20) 30183-5.
3. Ван Д., Ху Б., Ху С. и др. Клинические характеристики 138 госпитализированных пациентов с пневмонией, инфицированной новым коронавирусом 2019 г., в Ухане, Китай. ДЖАМА. 2020; 323 (11): 1061–1069. DOI: 10.1001 / jama.2020.1585.
4. Тан В., Чжао X, Ма Х, Ван В., Ниу П., Сюй В., Гао Г. Ф., Ву Г. Новый геном коронавируса, выявленный в группе случаев пневмонии – Ухань, Китай, 2019–2020 гг. Китай CDC Wkly. 2020; 2 (4): 61–62.
5. Wu Z, McGoogan JM. Характеристики и важные уроки вспышки коронавирусного заболевания 2019 г. (COVID-19) в Китае: краткое изложение отчета Китайского центра по контролю и профилактике заболеваний о 72314 случаях. ДЖАМА. 2020 doi: 10.1001 / jama.2020.2648.
6. Guan W, Ni Z, Hu Y et al (2020) Клинические характеристики новой коронавирусной инфекции 2019 г. в Китае. medRxiv. 10.1101 / 2020.02.06.20020974
7. Tang N, Li D, Wang X, Sun Z. Аномальные параметры коагуляции связаны с плохим прогнозом у пациентов с новой коронавирусной пневмонией. J Thromb Haemost. 2020; 18 (4): 844–847. DOI: 10,1111 / jth.14768.
8. Xu Z, Shi L, Wang Y, et al. Патологические данные COVID-19, связанные с острым респираторным дистресс-синдромом. Ланцет Респир Мед. 2020; 8 (4): 420–422. DOI: 10.1016 / S2213-2600 (20) 30076-X.
9. Мао Л., Ван М., Чен С. и др. (2020) Неврологические проявления у госпитализированных пациентов с COVID-19 в Ухане, Китай: ретроспективное исследование серии случаев. medRxiv. 10.1101 / 2020.02.22.20026500
10. Линь Л., Ли Т.С. Интерпретация «Руководства по диагностике и лечению новой коронавирусной инфекции (2019-nCoV) Национальной комиссии здравоохранения (пробная версия 5)» Чжунхуа И Сюэ За Чжи. 2020; 100: E001.
11. Инь С., Хуанг М., Ли Д., Тан Н. Различие в характеристиках коагуляции между тяжелой пневмонией, вызванной SARS-CoV2, и не-SARS-CoV2. J Тромб Тромболизис. 2020 DOI: 10.1007 / s11239-020-02105-8